Literature DB >> 12769682

Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening.

Richard M Eglen1, Rajendra Singh.   

Abstract

In this review, the applications of beta galactosidase complementation are described. alpha Complementation is a naturally occurring process in bacteria and in engineered cells, and can also occur in eukaryotic cells. Two forms of alpha complementation have been used in high throughput screening (HTS), in which interacting fragments complement with either low or high affinity. Low affinity complementation is used to monitor protein protein interactions, such as those occurring in homodimerization of the epidermal growth factor receptor (EGFR), and provides a robust screen for detection of EGFR inhibitors. High affinity complementation provides the basis for several HTS assays, in which analytes, such as cAMP or IP(3), are detected in crude cell lysates. A development of the latter approach is protein labeling, providing for measurement of cell protein expression and trafficking. Collectively, the use of beta galactosidase complementation provides a novel and flexible technology for highly sensitive, homogeneous HTS assay development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769682     DOI: 10.2174/138620703106298473

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  6 in total

1.  Firefly luciferase enzyme fragment complementation for imaging in cells and living animals.

Authors:  Ramasamy Paulmurugan; Sanjiv S Gambhir
Journal:  Anal Chem       Date:  2005-03-01       Impact factor: 6.986

2.  Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay.

Authors:  Karen M Kleman-Leyer; Tony A Klink; Andrew L Kopp; Thane A Westermeyer; Mark D Koeff; Brad R Larson; Tracy J Worzella; Cori A Pinchard; Sebastianus A T van de Kar; Guido J R Zaman; Jorrit J Hornberg; Robert G Lowery
Journal:  Assay Drug Dev Technol       Date:  2009-02       Impact factor: 1.738

3.  Modulation of PLAGL2 transactivation by positive cofactor 2 (PC2), a component of the ARC/Mediator complex.

Authors:  Sara J Wezensky; Tracey S Hanks; Michelle J Wilkison; Mary Cloud Ammons; Daniel W Siemsen; Katherine A Gauss
Journal:  Gene       Date:  2009-12-16       Impact factor: 3.688

4.  Expanding the utility of beta-galactosidase complementation: piece by piece.

Authors:  Ann-Marie Broome; Nihir Bhavsar; Gopalakrishnan Ramamurthy; Gail Newton; James P Basilion
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

Review 5.  Tools for GPCR drug discovery.

Authors:  Ru Zhang; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

6.  Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.

Authors:  Ankita Narayan; Amanda Hunkele; Jin Xu; Daniel L Bassoni; Gavril W Pasternak; Ying-Xian Pan
Journal:  Cell Mol Neurobiol       Date:  2020-10-08       Impact factor: 4.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.